Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma.

BACKGROUND The prognostic values of the International Prognostic Index (IPI) and the Follicular Lymphoma International Prognostic Index (FLIPI) have widely been demonstrated in diffuse large B-cell lymphoma and follicular lymphoma. No attempts to assess their applicability in MALT lymphoma have been made so far. PATIENTS AND METHODS A total of 143 patients with MALT-lymphoma were analysed. Parameters of both IPI and FLIPI were retrospectively assessed and correlated with relapse and time to relapse as markers of clinical course. RESULTS According to IPI, 96 patients (67%) were classified as low, 22 (15%) low-intermediate, 17 (12%) high-intermediate and 8 (6%) as high risk. FLIPI identified 99 patients (70%) at low risk, 35 (24%) at intermediate and 9 (6%) at high risk. After a median follow-up time of 39.5 months, 123 patients were alive and 46 patients had relapsed (median time to relapse 27 months). IPI significantly correlated with time to relapse, with the typical differentiation into low, low-intermediate and high risk groups. FLIPI divided patients into three groups, but the low and intermediate risk groups showed a similar clinical course. In terms of additional progonostic factors, univariate analysis suggested autoimmune disease and multifocal disease as correlated with relapse. Multiple regression analysis, however, identified only extragastric disease as predictive of relapse (p=0.001). CONCLUSION Our data demonstrate that both IPI and FLIPI are able to discriminate prognostic subgroups in patients with MALT-lymphoma. However, the low and intermediate group of the FLIPI did not appear to prognostically differ.

[1]  A. Chott,et al.  Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[3]  K. Turetschek,et al.  Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. , 2007, Anticancer research.

[4]  A. Chott,et al.  MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course , 2007, Leukemia.

[5]  K. Turetschek,et al.  Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma , 2007, Oncology.

[6]  K. Turetschek,et al.  Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Matsuno,et al.  Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  U. Jaeger,et al.  High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-up , 2005, Clinical Cancer Research.

[9]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[10]  S. Pileri,et al.  Fludarabine‐containing chemotherapy as frontline treatment of nongastrointestinal mucosa‐associated lymphoid tissue lymphoma , 2004, Cancer.

[11]  A. López-Guillermo,et al.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. , 2003, Blood.

[12]  T. Molina,et al.  T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. , 2001, Gastroenterology.

[13]  A. Chott,et al.  Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Ming-Qing Du,et al.  Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy , 2001, The Lancet.

[15]  F. Cavalli,et al.  The gastric marginal zone B-cell lymphoma of MALT type. , 2000, Blood.

[16]  S. Pileri,et al.  From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities? , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Stolte,et al.  Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. , 1997, Gastroenterology.

[18]  G. Salles,et al.  Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. López-Guillermo,et al.  Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.